Polymorphism - Integrated approach from high-throughput screening to crystallization optimization

被引:51
作者
Hilfiker, R [1 ]
Berghausen, J [1 ]
Blatter, F [1 ]
Burkhard, A [1 ]
De Paul, SM [1 ]
Freiermuth, B [1 ]
Geoffroy, A [1 ]
Hofmeier, U [1 ]
Marcolli, C [1 ]
Siebenhaar, B [1 ]
Szelagiewicz, M [1 ]
Vit, A [1 ]
von Raumer, M [1 ]
机构
[1] Solvias AG, CH-4002 Basel, Switzerland
关键词
carbamazepine; crystallization; high-throughput; polymorphism; screening;
D O I
10.1023/A:1025409608944
中图分类号
O414.1 [热力学];
学科分类号
摘要
Crystal structure (polymorphism) as well as crystal shape (morphology) and size have a huge practical and commercial impact on active substances all the way from research to manufacture of the final product. For an optimal development process, it is important to have an integrated approach to these issues ranging from a systematic polymorphism screening to a controlled scale-up of the crystallization process. The polymorphism program has to be tailored according to the development stage. Particularly suitable for an early development stage is a high-throughput polymorphism screening, which is the basis for a more thorough investigation if the product proceeds further in development. Such a comprehensive polymorphism investigation involves further crystallization experiments and extensive physicochemical characterization of the various forms. In this article the high-throughput polymorphism screening method that we have developed is described. Using carbamazepine as an example, the power of this high-throughput polymorphism screening system is demonstrated. Not only were all published forms found, but also new forms were identified. In the second part of the article, important considerations for crystallization optimization are discussed, again using the example of carbamazepine.
引用
收藏
页码:429 / 440
页数:12
相关论文
共 33 条
[1]   Laser Raman spectroscopic analysis of polymorphic forms in microliter fluid volumes [J].
Anquetil, PA ;
Brenan, CJH ;
Marcolli, C ;
Hunter, IW .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (01) :149-160
[2]  
AUER ME, 1998, 23 ANN M SWISS SOC T
[3]   Seeding the desired polymorph: Background, possibilities, limitations, and case studies [J].
Beckmann, W .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2000, 4 (05) :372-383
[4]   Crystallisation of the stable polymorph of hydroxytriendione: Seeding process and effects of purity [J].
Beckmann, W ;
Otto, W ;
Budde, U .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2001, 5 (04) :387-392
[5]   HEAT OF FUSION MEASUREMENT OF A LOW MELTING POLYMORPH OF CARBAMAZEPINE THAT UNDERGOES MULTIPLE-PHASE CHANGES DURING DIFFERENTIAL SCANNING CALORIMETRY ANALYSIS [J].
BEHME, RJ ;
BROOKE, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1991, 80 (10) :986-990
[6]  
Bernstein J., 2002, IUCR MONOGRAPHS CRYS, V14
[7]  
Blagden N, 1999, CHEM BRIT, V35, P44
[8]  
Brittain H. G., 1999, Polymorphism in Pharmaceutical Solids
[9]   X-ray characterization of the triclinic polymorph of carbamazepine [J].
Ceolin, R ;
Toscani, S ;
Gardette, MF ;
Agafonov, VN ;
Dzyabchenko, AV ;
Bachet, B .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (09) :1062-1065
[10]  
DeCamp WH, 2001, AM PHARM REV, V4, P70